Additional partnerships for CBS9106 in Japan, China, Taiwan and South Korea
First written in FY2016. 6 of 10 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026DroppedAnnual report
「The company also terminated its licensing agreement with Stemline for CBS9106, which had continued since December 2014, and now holds all rights itself.」
The previous objective of pursuing additional partnerships covering Japan, China, Taiwan and South Korea is not mentioned in this filing and has been replaced by the termination of the agreement with Stemline and the company’s holding of all rights itself. - FY2020RestatedAnnual report
「In December 2014, the company entered into a license agreement with Stemline granting exclusive worldwide rights to CBS9106, initially excluding Japan, China, Taiwan and South Korea, but amended in August 2018 to remove these excluded territories.」
The company reconfirmed the existing additional alliance granting rights worldwide, including Japan, China, Taiwan and South Korea. - FY2019-Q1AchievedAnnual report
「For CBS9106, the company completed additional alliance arrangements in Japan, China, Taiwan and South Korea, which had been excluded territories under the license agreement with U.S.-based Stemline Therapeutics, Inc. (including expanding the territories in which rights are granted to Stemline and extending the technical advisory fee period). Going forward, the company will seek to bring forward milestone revenue and other payments by supporting Stemline's advancement of the clinical trials.」
The company completed additional alliance arrangements, including an expansion of the territories in which rights are granted to the existing Stemline, rather than acquiring a new partner. - FY2018ReframedAnnual report
「Japan, China, Taiwan and South Korea were added to the territory specified in the original agreement as “worldwide, excluding Japan, China, Taiwan and South Korea.” As a result, the company grants Stemline exclusive worldwide rights, including the right to sublicense, to develop, manufacture and commercialize CBS9106 and related compounds.」
The plan changed from the previous policy of seeking new alliance partners in the excluded territories to additionally granting the existing Stemline rights covering those territories and the rest of the world. This does not explicitly state that a new partner will be acquired. - FY2018-Q3RestatedAnnual report
「For CBS9106, the company is also pursuing additional alliance activities in Japan, China, Taiwan and South Korea, which are excluded territories under the license agreement with U.S.-based Stemline Therapeutics, Inc. (hereinafter, “Stemline”).」
The company continues to pursue additional alliance activities in Japan, China, Taiwan and South Korea, which are outside the scope of Stemline's license. - FY2018-Q2RestatedAnnual report
「For CBS9106, the company is also pursuing additional alliance activities in Japan, China, Taiwan and South Korea, which are excluded territories under the license agreement with U.S.-based Stemline Therapeutics, Inc. (hereinafter, “Stemline”).」
The company continues to pursue additional alliance activities in Japan, China, Taiwan and South Korea, which are outside the scope of Stemline's license. - FY2017RestatedAnnual report
「The company is seeking new alliance partners in Japan, China, Taiwan and South Korea, which are excluded from its license agreement with Stemline.」
The company continues to pursue additional alliance activities in territories outside the scope of Stemline's agreement. - FY2017-Q3RestatedAnnual report
「For CBS9106, the company is also pursuing additional alliance activities in Japan, China, Taiwan and South Korea, which are excluded territories under the license agreement with Stemline Therapeutics, Inc.」
The company continues to pursue additional alliance activities in Japan, China, Taiwan and South Korea, which are outside the scope of Stemline's license. - FY2017-Q1RestatedAnnual report
「The company is also pursuing alliance activities for CBS9106, which is at the Phase 1 clinical trial stage, covering Japan, China, Taiwan and South Korea.」
The company continues to pursue additional alliance activities in Japan, China, Taiwan and South Korea, which are outside the scope of Stemline's license. - FY2016First statedAnnual report
「While supporting the clinical trials being conducted by Stemline, the company is currently seeking alliance partners in Japan, China, Taiwan and South Korea.」
The company is seeking separate alliance partners for the territories excluded from the existing license.